Hepatocyte growth factor (HGF) has been shown to induce angiogenesis in vivo and has potential as a candidate gene for 'therapeutic angiogenesis'. In vivo, two isoforms of HGF, HGF 723 and HGF 728 , consisting of 723 and 728 amino acids, are generated through alternative splicing between exons 4 and 5, but the biological effects of their coexpression have not yet been elucidated. In this study, we generated a series of genomic-complementary DNA (cDNA) hybrids of the HGF gene by inserting various truncated intron 4 into the junction of exons 4 and 5 of HGF cDNA and analyzed the biological activities of these hybrid constructs. We showed that: (1) the hybrid called HGF-X7, which contained 1502 base pairs of intron 4, could drive a higher level of HGF expression than other hybrid constructs and cDNAs of each isoform alone; (2) the pCK vector was most efficient for the gene expression of HGF-X7; (3) coexpression of both isoforms of HGF could more efficiently induce the migration of human umbilical vein endothelial cell (HUVEC) and of the mouse myoblast cell line C 2 C 12 myoblasts than a single isoform of HGF and human vascular endothelial growth factor (VEGF) 165 at a given concentration; (4) intramuscular administration of pCK-HGF-X7 resulted in transient and localized HGF expression in the injected muscle without an increase in the HGF protein levels in other tissues including serum; and (5) intramuscular injection of pCK-HGF-X7 could more efficiently increase the number of angiographically recognizable collateral vessels, as well as improve an intra-arterial Doppler wiremeasured blood flow in the rabbit model of hindlimb ischemia when compared with the identical vector encoding VEGF 165 gene. These results showed that transfer of the genomiccDNA hybrid of the HGF gene could be used as a potential therapeutic approach to human vascular diseases.
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Introduction
Peripheral arterial disease is a common disorder usually caused by atherosclerotic changes in the arteries supplying blood to the lower extremities, resulting in ischemic limb disease. 1 Critical limb ischemia denotes a condition of severe arterial obstruction because of advanced peripheral arterial disease, which is associated with the breakdown of the skin or pain in the lower limb at rest. 2 The natural history of critical limb ischemia has been well documented to have an inexorable downhill course, frequently leading to the amputation of the affected limb, despite its associated morbidity, mortality and functional implications. 3, 4 It has been estimated that approximately 150 000 subjects per year require lower-limb amputations for ischemic diseases in the United States alone. Therefore, there is an urgent need for novel treatment strategies for subjects with critical limb ischemia. 5, 6 The term 'therapeutic angiogenesis' was coined to describe the intervention used to stimulate or induce neovascularization by administering angiogenic factors, either as recombinant proteins or as genes, to the ischemic sites. 7 Therapeutic angiogenesis represents a novel strategy for the treatment of cardiac and vascular diseases. 8 With the recent advances in gene therapy, several angiogenic genes, including fibroblast growth factor 4 (FGF-4), hepatocyte growth factor (HGF), human vascular endothelial growth factor (VEGF) 121 , VEGF 165 and VEGF-2, have been delivered using naked DNA and adenovirus-based vectors intramuscularly or intraarterially to achieve therapeutic effects with varying degrees of success. 7, [9] [10] [11] [12] [13] [14] [15] [16] HGF has been shown to be a potent angiogenic growth factor, stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. 17, 18 A gene encoding human HGF is located at chromosome 7q21.1 and comprises 18 exons and 17 introns and simultaneously expresses two isoforms of HGF, one consisting of 728 amino acids (HGF; here HGF 728 ) and the other called deleted HGF having 723 amino acids (dHGF; here HGF 723 ). 19 HGF 723 is made through alternative splicing, which occurs between exons 4 and 5, resulting in the deletion of five amino acids (Phe-Leu-Pro-Ser-Ser; FLPSS). 20 Although both HGF 728 and HGF 723 share several biological functions, they are different in terms of immunological and several biological properties, 21 and thus far only one isoform (HGF) has been used in the gene therapy settings. 9, [15] [16] [17] [22] [23] [24] [25] [26] However, the biological effects of the coexpression of HGF 723 and HGF 728 have not yet been elucidated. In this study, we developed a genomic-complementary DNA (cDNA) hybrid of the HGF gene, which can simultaneously express HGF 723 and HGF 728 with high efficiency, and applied this hybrid HGF construct for angiogenic gene therapy in the rabbit ischemic hindlimb disease model.
Results
High-level expression of two isoforms of HGF by engineering the intron and cDNA sequences
In vivo, two isoforms of HGF are made by alternative splicing: HGF 723 and HGF 728 . 20 To mimic this situation, the HGF gene was engineered to simultaneously produce these two species by constructing the hybrid between the genomic and cDNA sequences. In the human genome, intron 4 of the HGF gene is involved in alternative splicing ( Figure 1a ). Because intron 4 is relatively long (4.9 kb), we first determined the minimum length of intron 4 that would allow both high-efficiency splicing and high-level gene expression. Various deletions of intron 4 were inserted to the junction of exons 4 and 5 of the cDNA, resulting in a series of genomic-cDNA hybrid HGF constructs as summarized in Figure 1a , which were subsequently cloned into an expression vector called pCP. 27 To examine whether these hybrid constructs could indeed produce both HGF 723 and HGF 728 by alternative splicing, pCP expression vectors containing various deletions were transfected to 293T cells, and their RNA products were analyzed by reverse transcriptase-PCR using a pair of specific primers that can differentiate two RNA species of HGF. As shown in Figure 1b , two DNA bands of 127 and 142 bp, each representing HGF 723 and HGF 728 mRNAs, were detected in all deletion constructs. The protein level of total HGF was determined by enzyme-linked immunosorbent assay (ELISA), which can detect all HGF isoforms, using the culture supernatant of transfected cells. A deletion construct named HGF-X7, containing only 1501 out of the 4941 bp long intron 4, consistently gave the highest level of HGF protein when compared with six other deletions as well as with non-splicing cDNA constructs expressing only one isoform of HGF (Figure 1c) .
The actual presence of each isoform of HGF protein in the culture supernatant was confirmed by peptide mapping using trypsin hydrolysis followed by liquid chromatography-mass spectrometry/mass spectrometry. One representative result is shown in Figure 1d . The control vectors containing cDNA sequences for either isoform produced one protein species only. However, both HGF 723 and HGF 728 were observed at a similar ratio in the culture supernatant from cells transfected with an HGF-X7-containing vector.
A high-level gene expression of the intron-cDNA hybrid construct was more evident in vivo. In all, 250 mg of pCP-HGF-X7, pCP-HGF 723 or pCP-HGF 728 construct was injected into the tibialis cranialis muscle of BALB/c mice. After 7 days, the injected muscle areas were excised, the total protein extracts were prepared and the HGF level was measured using ELISA. pCP-HGF-X7 reproducibly produced more than threefold higher level of HGF than the same expression vectors expressing one isoform of HGF (Figure 1e ). On the basis of these results, a hybrid sequence, HGF-X7, was chosen for further experiments.
Comparative analysis of expression vectors for HGF-X7
To develop a high-efficiency expression vector for HGF-X7, this hybrid sequence was inserted into three different expression plasmids containing the human cytomegalovirus major immediate early promoter: pCP, 27 pVAX1 (Invitrogen, Carlsbad, CA, USA) and pCK. 27 These expressing constructs were then compared for their gene expression efficiencies both in vitro and in vivo. HGF ELISA of the culture supernatant from 293T cells transfected with these expressing vectors showed that pCK-HGF-X7 produced an almost 65% higher level of HGF proteins than pCP-HGF-X7 and pVAX1-HGF-X7 (Figure 2a) . Consistently, HGF ELISA of the tissue lysates from the injected muscles of mice at 7 days after intramuscular injection of these constructs revealed that the level of HGF produced from pCK-HGF-X7 was almost 3.6-fold higher than those from pCP-HGF-X7 and pVAX1-HGF-X7 (Figure 2b ). Therefore, pCK-HGF-X7 was chosen as the HGF-X7-expressing construct for the later experiments.
Effect of coexpression for both HGF protein isoforms on cell migration
To make sure that the coexpression of two isoforms of HGF from the hybrid sequence produces expected biological activities, the cell migration assay was performed, using human umbilical vein endothelial cells (HUVECs) and the mouse myoblast cell line (C 2 C 12 ). Five expression vectors were transfected to 293T cells, each containing HGF-X7, HGF 723 , HGF 728 , VEGF 165 or no DNA sequences. The culture supernatants were taken, and the level of HGF protein was measured by ELISA and diluted to 50 ng ml -1 of total HGF protein. The diluted culture supernatants were added to respective cells to perform the migration assay. As clearly shown in Figures 3a and b , an expression vector containing the HGF-X7 sequence more efficiently induced the cell migration in both HUVECs and C 2 C 12 cells than three other pCK constructs producing one isoform of HGF and VEGF 165 .
In vivo kinetics of HGF expression from pCK-HGF-X7
The success of naked DNA gene therapy depends highly on the level of gene expression. We previously reported a high-efficiency expression system called pCK that is characterized by the presence of not only the full-length promoter but also the entire untranslated exon sequences and the truncated intron 1 sequence from the major immediate early region of human cytomegalovirus. 27 Coexpression of HGF two isoforms improves critical limb ischemia W-B Pyun et al
The hybrid HGF-X7 sequence was cloned into pCK, resulting in pCK-HGF-X7, and the gene expression kinetics were studied in various animal models.
First, the dosage effect of plasmid DNA was studied. Various concentrations of pCK-HGF-X7 were injected into the tibialis cranialis of BALB/c mice (n ¼ 10 per dose group). After 7 days, total proteins were extracted from the injected site and analyzed using ELISA. As shown in Figure 4a , the HGF level of pCK-HGF-X7-injected mice was significantly higher than that of the negative control group at all DNA concentrations used in the experiment (Po0.001). The HGF level increased with the increase in DNA amounts, and reached the peak at 100 mg. There was no statistically significant difference in HGF levels between 100, 250 and 500 mg dose groups. These results showed that the HGF protein level could increase in 
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W-B Pyun et al a dose-responsive manner in the range of 25-100 mg of pCK-HGF-X7, before reaching a plateau. We chose 250 mg, the median value of plateau dose range, as the dose per injection for further experiments.
To study the kinetics of HGF expression, 250 mg of pCK-HGF-X7 DNA was injected into the skeletal muscle of BALB/c mice (n ¼ 5-15 per time point) or New Zealand white rabbits (n ¼ 3-8 per time point), and the level of HGF was measured using ELISA. The level of HGF protein in the injected muscle of the mice was detectable: 0.97 ng mg -1 of tissue protein from day 1, and gradually increasing until day 7 and reaching 5.23 ng mg -1 . More than 4.7 pg mg -1 of tissue protein of HGF was detected for 3 weeks. The HGF level was decreased to the background level at day 28 (Po0.001, Figure 4b ). Similar kinetics of HGF expression were observed in the rabbit skeletal muscle (P ¼ 0.003, Coexpression of HGF two isoforms improves critical limb ischemia W-B Pyun et al Figure 4c ). These results suggested that a single intramyocardial injection of pCK-HGF-X7 allows a significant level of HGF to be expressed for 2 to 3 weeks around the injection site.
The level of HGF was also examined in the serum and other organs of mice and rats. At 5 or 7 days after administration of 250 mg of pCK-HGF-X7, when a significant level of HGF was detected in the injected muscle of mice or heart of rats, mice (n ¼ 10 per treatment group) or rats (n ¼ 5 per treatment group) were killed, and various tissues were collected, followed by ELISA for HGF. HGF level was lower than the detection limit (125 pg ml -1 ) in most tissues (data not shown). Except in the injected muscles and hearts, there was no significant difference in the HGF protein level between the pCK-HGF-X7-treated animals and the negative control group. These results clearly indicated that a single intramuscular administration of pCK-HGF-X7 could result in transient and localized HGF expression in the injected muscle without an increase in the HGF protein levels in other tissues.
Intramuscular administration of pCK-HGF-X7 DNA enhances collateral artery formation and the blood flow in rabbits
We tested whether the intramuscular transfer of pCK-HGF-X7 could be used to enhance the collateral artery formation in a rabbit model of limb ischemia. As a positive control, pCK-VEGF 165 , 27 which has previously been tested as an angiogenic medicine in a phase I human clinical trial, 11 was used. Ischemia was induced in the hindlimb of 36 New Zealand white rabbits by the ligation of the distal external iliac artery and also the complete excision of the femoral artery (day 0). At 10 days after the induction of limb ischemia (day 10), a total of 1 mg of pCK (negative control, n ¼ 11), pCK-VEGF 165 (positive control, n ¼ 9) or pCK-HGF-X7 (n ¼ 16) was administered into the adductor and semimembranous muscles at four separate sites (250 mg in 250 ml per site).
The formation of collateral vessels was assessed by angiography with a 3F catheter placed at the left internal iliac artery in the ischemic limb on days 10 and 40.
Representative angiograms recorded from the experimental groups at days 10 and 40 are shown in Figure 5a . In pCK-HGF-X7-treated animals, the development of the collateral artery in the medial thigh was more evident when compared with the pCK and pCK-VEGF 165 groups (Figure 5b) . The baseline values for the number of collateral vessels measured at day 10 were 42.55 ± 2.70, 47.00±3.22 and 46.63±2.72 for the pCK, pCK-VEGF 165 and pCK-HGF-X7 treatment groups, respectively, and no intergroup differences were observed (P ¼ 0.531). Angiography performed at day 40 showed that the average number of collateral vessels in the pCK group was 45.45 ± 2.71, which was not significantly different from the baseline value measured at day 10 (P ¼ 0.184). In the pCK-VEGF 165 group, the number of collateral vessels increased to 53.22 ± 4.26 by 13% from the baseline (P ¼ 0.057). In the pCK-HGF-X7 treatment group, the average number of collateral vessels was 62.69 ± 3.51, showing 34% increase compared with the baseline value (Po0.001). These results suggested that intramuscular 
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W-B Pyun et al transfer of pCK-HGF-X7 could enhance the collateral formation more efficiently than the identical vector expressing VEGF 165 . We also examined the effects of pCK-HGF-X7 injection on the blood flow in the same rabbit model. In each treatment group, the rate of blood flow was measured by placing a Doppler probe at the opening of the internal iliac artery at days 10 and 40 (Figure 5c ). At day 10, the rates of blood flow in the internal iliac artery were 33.34±2.29, 32.42±3.09 and 34.19±2.80 ml min -1 for the pCK, pCK-VEGF 165 and pCK-HGF-X7 treatment groups, respectively, and there were no significant intergroup differences (P ¼ 0.913). At day 40, the rate of blood flow in the internal iliac artery was 52.43±3.15 ml min -1 for the pCK-HGF-X7 treatment group (53.4% increase compared with baseline value, Po0.005), whereas it was 43.98 ± 3.12 ml min -1 for the pCK group (31.9% increase compared with baseline value, Po0.01) and 44.24 ± 2.51 ml min -1 for the pCK-VEGF 165 group (36.5% increase compared with baseline value, Po0.05). These results showed that intramuscular delivery of pCK-HGF-X7 could efficiently increase the blood flow in the internal iliac artery of ischemic hindlimb of rabbits.
Discussion
The results shown in this report demonstrate that the genomic-cDNA hybrid of the HGF gene can express both isoforms of HGF protein in an efficient manner, and furthermore that direct in vivo delivery of this sequence could enhance the collateral formation and blood flow more effectively in the rabbit ischemic hindlimb model than when VEGF 165 was expressed in the identical vector. The data presented in this report are consistent with previous results showing the improvement by pCK-HGF-X7 of the myocardial perfusion, viability and left ventricular function, as measured by magnetic resonance imaging 28, 29 and 99mTc-methoxyisobutylisonitrile Single Photon Emission Computed Tomography 30 in the porcine heart disease model.
The two major factors determining the success of angiogenic gene therapy is the gene itself and the vector 
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that determines the level of the transgene product. While screening various genes for their angiogenic activity, we chose to study HGF because its biological activity seems to show potential as a therapeutic gene in the context of gene therapy. The HGF gene is present in two isoforms produced by alternative splicing, but the biological role(s) of these isoforms has not yet been elucidated. Therefore, we decided to express the two isoforms similar to the situation in vivo. Because the alternative splicing occurs between exons 4 and 5, intron 4 was cloned and inserted into the appropriate junction in the HGF cDNA. Our results clearly indicated that such a genomic-cDNA hybrid could indeed produce two isoforms at a high level. This study showed that HGF-X8, which contains the shortest length of intron 4 sequences of the HGF gene among the tested HGF-X constructs, could produce both isoforms of RNA. This result indicated that the presence of 5 0 246 bp and 3 0 307 bp, out of the original 4941 bp of intron 4 was sufficient to generate alternative splicing. However, gene expression efficiency of HGF-X8 was significantly lower than that of HGF-X7, which contains 5 0 246 bp and 3 0 1256 bp of intron 4, suggesting that nucleotide sequences between 3686 and 4634 of intron 4 are required for efficient splicing and gene expression.
VEGF 165 is one of the most intensively studied therapeutic genes in angiogenic gene therapy, including various preclinical experiments and clinical studies. 11, [31] [32] [33] [34] [35] In our study the VEGF 165 gene was used as a sort of control for the comparison of therapeutic potency. Our data showed that intramuscular injection of HGF construct, which is designed to express both isoforms of HGF protein, could induce the collateral artery formation more efficiently than the identical DNA vector expressing VEGF 165 . This is consistent with the previous report showing that HGF was more angiogenic than VEGF 165 in relation to recombinant protein therapy. 18 As an endothelium-specific mitogen, VEGF 165 can induce migration and proliferation of endothelial cells. However, because of the lack of its receptors in vascular smooth muscle cells, VEGF stimulates neither migration nor proliferation of these cells. 17 In contrast, HGF has been shown to stimulate the migration of both endothelial cells and vascular smooth muscle cells, in addition to mitogenic activity on endothelial cells. 17 Moreover, HGF has been shown to stimulate various metalloproteases, such as matrix metalloproteinase-1, through upregulation of its activity. 36, 37 These distinguishing features of HGF would be a great advantage in the generation and early maturation of newly formed blood vessels when compared with VEGF. Taken together, although the actual mechanism has yet to be unraveled, HGF is expected to be more promising than VEGF 165 in the gene therapy setting.
This study showed that the levels of HGF in the injected muscles peaked on day 7 and then gradually decreased. One possible explanation for this decrease is the gradual degradation of exogenously added DNA as time progresses. 38 The HGF level in the serum and other organs after DNA injection was very low or undetectable even when a high level of HGF protein was readily detected in the injected muscle. This is somewhat different from the previous observation that a significant level of serum interleukin-1 receptor antagonist (IL-1Ra) protein could be found after intramuscular administration of IL-1Ra DNA. 38 One possible explanation for this discrepancy is the high affinity of HGF to heparan sulfate proteoglycan on the cell surface and in the extracellular matrix. Indeed, the serum level of HGF protein has been reported to increase after the injection of soluble heparin in humans. 39 Our data showing that a single intramuscular administration of HGF-X7 DNA could result in a transient and localized expression in the injected muscle area without systemic elevation of HGF level suggest that HGF DNA transfer technology could minimize the potential risk of an unexpected angiogenesis in areas other than the injected site.
To our knowledge, this study provided the first demonstration that coexpression of two isoforms of HGF protein could more efficiently induce the migration of both HUVEC and C 2 C 12 myoblast when compared with a single isoform of HGF or VEGF 165 . Endothelial migration is deeply associated with angiogenesis, and migration of skeletal muscle precursor cells is a crucial step in skeletal muscle development and postlesional muscle regeneration. 18, 40, 41 Therefore, coexpression of both isoforms of HGF, which can be achieved by introducing the alternative splicing function to the expression system, may provide an effective way of inducing neovascularization and regeneration of ischemic tissues in human critical limb ischemia that may result from ischemic diabetic complications and renal failureassociated cases.
Materials and methods

Cloning of genomic-cDNA hybrids of HGF gene and construction of expression vector
A series of genomic-cDNA hybrid sequences of the HGF gene (HGF-Xs) were generated using PCR, as described in detail by Kim et al. 42 These HGF fragments were cloned into three expression vectors: pCK, 27 pCP 27 and pVAX1 (Invitrogen). The procedure for making pCKand pCP-based HGF-X expression vectors was described previously. 42 For pVAX1-HGF-X7, the NheI/ApaI fragment of pCP-HGF-X7, which contains HGF-X7, was inserted into the NheI/ApaI site of pVAX1 vector. All expression vectors were purified using an EndoFree plasmid Maxi or Giga prep kit (Qiagen, Hamburg, Germany), dissolved in 0.9% NaCl, diluted to 1-5 mg ml -1 and stored at À20 1C before use.
Transfection, ELISA and reverse transcriptase-PCR
For a comparative analysis on the HGF-X expressing constructs, pCP-based HGF-X expressing constructs were transfected into 293T cells using FuGENE6 (Roche Diagnostics, Mannheim, Germany) (n ¼ 15 per group).
27
As controls, pCP-HGF 723 and pCP-HGF 728 were used. At 2 days after transfection, the culture supernatants were subjected to human HGF ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's recommendations. In addition, total cellular RNAs were extracted from the transfected 293T cells using the Trizol method (Gibco BRL, Grand Island, NY, USA) and subjected to reverse transcription to obtain cDNA. Using cDNA as a template DNA, PCR amplification was then carried out using primers, which is designed to distinguish mRNA of HGF 723 from HGF 728 . The amplified PCR products corresponded to the boundary region between exons 4 and 5 of the HGF gene; HGF 728 gene For the comparative analysis of expression vectors for HGF-X7, 2 mg of pCP-HGF-X7, pVAX1-HGF-X7 and pCK-HGF-X7 were transfected to 293T cells using FuGENE6 (n ¼ 5 per group). At 2 days after transfection, the culture supernatants were subjected to human HGF ELISA.
Preparation of HGF protein samples for mass spectrometry analysis
To analyze the simultaneous expression of two isoforms produced from naked DNA expression vectors, total HGF proteins were isolated from culture supernatants of 293T cells transfected with respective expression vectors, using cation-exchange chromatography (HiTrap SP FF column; GE Healthcare, Piscataway, NJ, USA) and heparin-affinity chromatography (HiTrap Heparin HP column; GE Healthcare). Affinity-purified HGF protein samples were subjected to a routine trichloroacetic acid/acetone precipitation procedure to remove detergents added during the purification process. To generate peptides covering different sequences, HGF protein samples were separately treated with a digestion buffer (100 mM TrisHCl, pH 7.8, 10 mM CaCl 2 ) and trypsin as a proteolytic enzyme for 14 h at 24 1C. The expected peptide sequences from HGF 723 or HGF 728 after trypsin hydrolysis were CQPWSSMIPHEHSYR or CQPWSSMIPHEHSFLPSSYR.
Micro liquid chromatography-mass spectrometry/mass spectrometry analysis
Relative quantification analyses of HGF 723 and HGF 728 were carried out by comparing selected ion chromatograms of unique tryptic digest peptides for each HGF isoform. Selected ion chromatograms obtained from liquid chromatography-mass spectrometry/mass spectrometry analysis have been used in the relative quantification of peptides or proteins. Digested proteins were loaded onto fused silica capillary columns (100 mm inner diameter and 360 mm outer diameter) containing 8 cm of 5 mm particle size Polaris C-18 column material (Metachem, Ventura, CA, USA) using a pressure bomb.
The column was placed inline with an Agilent HP1100 quaternary LC pump (Agilent, Santa Clara, CA, USA), and a splitter system was used to achieve a flow rate of 250nl min -1 (high-performance liquid chromatography flow rate 0.1 ml in -1 ). Buffer A (5% acetonitrile and 0.1% formic acid) and buffer B (80% acetonitrile and 0.1% formic acid) were used to make a 110-min gradient. The gradient profile started with 5 min of 100% buffer A, followed by a 70-min gradient from 0 to 55% buffer B, a 30-min gradient from 55 to 100% buffer B and a 5-min gradient of 100% buffer B. Eluted peptides were directly electrosprayed into an LTQ linear ion trap mass spectrometer (ThermoFinnigan, Palo Alto, CA, USA) by applying 2.3 kV of DC voltage. A data-dependent scan consisting of one full mass spectrometry (MS) scan (400-1400 m/z) and 10 data-dependent MS/MS scans was used to generate MS/MS spectra of eluted peptides. Normalized collision energy of 35% was used throughout the data acquisition. MS/MS spectra were searched against an in-house protein database containing all HGF sequences using TurboSequest, and static modification of cysteine (+57) was considered in the search. DTASelect was used to filter the search results, and the following Xcorr values were applied to different charge states of peptides: 1.8 for singly charged peptides, 2.5 for doubly charged peptides and 3.5 for triply charged peptides. All the filtered MS/MS spectra were manually validated to confirm the database search results.
Migration assay
HUVEC (CC-2517; Cambrex BioScience, Charles City, IA, USA) and C 2 C 12 (CRL-1772; ATCC, Manassas, VA, USA) migration was evaluated by the modified Boyden chamber assay. 18, 43, 40 In all, 24 transwell cell culture chamber inserts (Corning, Corning, NY, USA) with porous polycarbonate filters (8 mm pore size) were coated with 1% gelatin in phosphate-buffered saline. HUVECs or C 2 C 12 suspended in M199 or Dulbecco's modied Eagle's medium supplemented with 1 or 3% of fetal bovine serum, respectively, were added to the inserts at 4 Â 10 4 or 1 Â 10 4 cell per well. Test substances (supernatants from the 293T cells transfected with pCK, pCK-HGF 723 , pCK-HGF 728 , pCK-HGF-X7 or pCK-VEGF 165 ) were diluted to 50 ng ml -1 of total HGF protein in M199 or Dulbecco's modied Eagle's medium supplemented with 1 or 3% of fetal bovine serum, respectively, and 600 ml of the final dilution was placed in the lower chamber. HUVECs or C 2 C 12 were allowed to migrate for 2 or 3 h at 37 1C in an incubator. The filters were then rinsed with phosphate-buffered saline, fixed with 4% formaldehyde for 10 min and stained with 0.2% crystal violet. Migration was quantified by counting cells of five high-power fields (Â 200) in each well with Image-Pro plus (Media Cybernetics, Bethesda, MD, USA) (n ¼ 20 or 10 per treatment group in HUVECs or C 2 C 12 ).
Plasmid DNA injection and ELISA
For in vivo HGF expression analysis in mice, 5-week-old BALB/c mice (Charles River, Wilmington, MA, USA) were anesthetized with ketamine (1.35 mg per mouse)/xylazine (66 mg per mouse) and injected with plasmid DNAs. For the comparison of in vivo HGF expression among HGF-X7, HGF 723 cDNA and HGF 728 cDNA, 250 mg of pCP-HGF-X7, pCP-HGF 723 or pCP-HGF 728 construct was injected into the tibialis cranialis muscle of BALB/c mice (5 weeks old, male; Charles River), and mice were killed on day 7 (n ¼ 10 per group). For the comparison of in vivo HGF expression among expression vectors containing HGF-X7, 250 mg of pCP-HGF-X7, pCK-HGF-X7 or pVAX1-HGF-X7 construct was injected into the tibialis cranialis muscle of BALB/c mice (5 weeks old, male; Charles River), and mice were killed on day 7 (n ¼ 10 per group).
To study the in vivo kinetics of HGF expression, BALB/c mice (5 weeks old, female and male; Charles River) or New Zealand white rabbit (3 months old, male; Central Lab. Animal Inc., Seoul, Korea) were injected with plasmid DNAs, respectively. For the dose-dependency analysis of HGF expression, five different concentrations (25, 50, 100, 250 or 500 mg) of pCK-HGF-X7 DNA were injected into the tibialis cranialis of the mice (n ¼ 10 per dose group), and animals were killed on day 7. For the time course analysis, 250 mg of pCK-HGF-X7 was injected into the tibialis cranialis of the mice (n ¼ 5-15 per Coexpression of HGF two isoforms improves critical limb ischemia W-B Pyun et al time point) or the rabbits (n ¼ 3-8 per time point). The mice were killed on days 1, 3, 5, 7, 10, 14, 21 and 28. The rabbits were killed on days 3, 7, 10 and 28.
For the analysis of HGF expression in other organs, 250 mg of pCK-HGF-X7 or pCK vector DNA as a negative control was injected into the tibialis cranialis of the mice (n ¼ 10 per treatment group), and they were killed at day 7.
To measure the level of HGF protein expression, the injected legs and hearts were collected, and 100 mg of the tissue was homogenized with 200 ml of cell lysis buffer as previously described. 38 For other organs, brain, heart, lung, spleen, kidney, stomach, small and large intestine, ovary and uterus (or seminal vesicle, prostate, testis and penis), the lymph node and sera were collected from rats. Then, 100 mg of each tissue was lysed with 500 ml of cell lysis buffer. The supernatants containing total protein were subjected to human HGF ELISA. The levels of HGF were normalized to the total amount of proteins from tissue lysates, as measured by DC protein assay kit (Bio-Rad, Hercules, CA, USA).
Induction of rabbit hindlimb ischemia and gene transfer
The angiogenic response to intramuscular administration of pCK-HGF-X7 in vascular insufficiency was investigated using a rabbit ischemic hindlimb model, which was designed to stimulate ischemia characteristic of patients with lower extremity arterial occlusive disease. 44 A total of 36 male New Zealand white rabbits (3.5-4 kg, MJ LTD, Daejeon, Korea) were provided with food and water ad libitum upon arrival, and allowed 7 days of rest before being subjected to the surgery. On day 0, the rabbits were anesthetized with an intramuscular injection of xylazine (5 mg kg ). A longitudinal skin incision was made in the left medial thigh, which was extended from the inguinal ligament to the patella along the femoral artery. The femoral fascia was removed, and the muscle was incised to expose the femoral artery and its branches. All branches of the femoral artery were removed and tied, and an incision was made from the proximal end of the femoral artery to the branching point of the saphenous artery and the popliteal artery. It was then checked for the presence of hemorrhage. Once the bleeding was controlled, the incised muscle, fascia and skin were sutured. After suture and disinfection of the incision area, all animals received gentamicin (3 mg kg -1 day -1 ) intramuscularly for 3 days to prevent infection. On day 10, selected internal iliac arteriography and Doppler analysis were performed to confirm the induction of the hindlimb ischemia. Each animal was then intramuscularly injected with a total dose of 1 mg pCK (n ¼ 11), pCK-VEGF 165 (n ¼ 9) or pCK-HGF-X7 (n ¼ 16) at four separate sites (that is, 250 mg per injection site) of the femoral muscle. The effects of pCK-HGF-X7 treatment were assessed by angiography, histological analysis and Doppler-based analysis on day 40.
Angiographic analysis in rabbit ischemic hindlimb model
As collateral vessels in the rabbit hindlimb ischemia model originate from the internal iliac artery, selected internal iliac arteriography was performed at days 10 and 40 to compare the development of collateral vessels. After cannulating the right carotid artery using Seldinger technique, a 3F catheter was inserted through the aorta and placed at the left internal iliac artery in the ischemic limb. Then, 5 ml of contrast agent was injected at a speed of 1 ml s -1 , and images were acquired using cine film to evaluate the extent of development of collateral vessels. For the quantitative measurement, three virtual lines were drawn on the image that was acquired 4 s after injection of the contrast agent, and the number of blood vessels crossing the lines was then counted in a blinded manner.
Doppler analysis in rabbit ischemic hindlimb model
On days 10 and 40, the rate of blood flow was measured by placing a Doppler probe at the opening of the internal iliac artery. A 0.014-inch Doppler guidewire was placed at the proximal part of the internal iliac artery, and after injecting papaverine (5 mg, Sigma, St Louis, MO, USA), the maximum rate of blood flow was measured. The rate of blood flow was calculated using the following equation: QD ¼ (pd 2 /4)(0.5 Â APV).
Statistics
Statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as the mean ± s.e.m. Results from in vitro and in vivo HGF expression and cell migration assay were analyzed using one-way analysis of variance followed by Dunnett's post hoc test to determine the significance of differences in multiple comparisons. Data from the in vivo kinetics study of HGF expression were analyzed using the Kruskal-Wallis test, whereas those from angiographical vessel count and internal iliac blood flow measurements were analyzed using Wilcoxon signed-ranks test. The Pvalues of o0.05 were considered significant.
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